Clearside Biomedical, Inc. announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, M.D., M.B.A., will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023. In his new advisory capacity, Dr. Ciulla will chair the Company's Scientific Advisory Board (SAB), sharing his medical expertise as a practicing retinal specialist and providing counsel on Clearside's ODYSSEY Phase 2b clinical trial and other suprachoroidal development programs.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.39 USD | +2.93% | -6.74% | +18.77% |
05-13 | HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating | MT |
05-09 | Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.77% | 101M | |
+9.74% | 118B | |
+10.77% | 106B | |
-10.94% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.30% | 15.97B | |
+6.56% | 14.03B | |
+17.26% | 11.67B |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023